Recent Updates
Recently added Catalysts

Lenabasum

Phase 3

Dermatomyositis | Small molecule | Other |Corbus Pharmaceuticals Holdings, Inc.|Last Updated: Aug 15, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment176
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03813160Trial to Evaluate Efficacy and Safety of Lenabasum in DermatomyositisPHASE3 COMPLETED 176 — — Dec 1, 2018Oct 1, 2021Aug 15, 2022 - —
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
Lenabasum 20 mgDRUGoral capsule
Lenabasum 5 mgDRUGoral capsule
PlaceboDRUGoral capsule
Unlock Study Design Details